Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H26O2 |
Molecular Weight | 310.4307 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C#C[C@@]1(CC[C@@]2([H])[C@]3([H])CCc4cc(ccc4[C@@]3([H])CC[C@@]21C)OC)O
InChI
InChIKey=IMSSROKUHAOUJS-MJCUULBUSA-N
InChI=1S/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3/t17-,18-,19+,20+,21+/m1/s1
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/536998 |
15.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | ENOVID Approved UseCombination oral contraceptives inhibit ovulation via a negative feedback mechanism on the hypothalamus, which alters the normal pattern of gonadotropin secretion of a follicle-stimulating hormone (FSH) and luteinizing hormone by the anterior pituitary. The follicular phase FSH and midcycle surge of gonadotropins are inhibited. In addition, combination hormonal contraceptives produce alterations in the genital tract, including changes in the cervical mucus, rendering it unfavorable for sperm penetration even if ovulation occurs. Changes in the endometrium may also occur, producing an unfavorable environment for nidation. Combination hormonal contraceptive drugs may alter the tubal transport of the ova through the fallopian tubes. Progestational agents may also alter sperm fertility. Launch Date-2.78207988E11 |
|||
Primary | ENOVID Approved UseMenstrual disorder |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
175 pg/mL |
50 μg single, oral dose: 50 μg route of administration: Oral experiment type: SINGLE co-administered: |
ETHINYL ESTRADIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
963 pg × min/mL |
50 μg single, oral dose: 50 μg route of administration: Oral experiment type: SINGLE co-administered: |
ETHINYL ESTRADIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6 h |
50 μg single, oral dose: 50 μg route of administration: Oral experiment type: SINGLE co-administered: |
ETHINYL ESTRADIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | yes (pharmacogenomic study) Comment: majority of tested variants exhibited decreased clearance values compared to wild type, except for CYP2C9*40 and *36 |
PubMed
Title | Date | PubMed |
---|---|---|
Letter: Oral contraceptives and malignant hepatoma. | 1976 Feb 28 |
|
Cardiovascular birth defects and antenatal exposure to female sex hormones. | 1977 Jan 13 |
|
Asymptomatic liver cell adenomas. Another case of resolution after discontinuation of oral contraceptive use. | 1978 Apr 21 |
|
Oral contraception and cerebral thrombosis in a Jamaican. | 1983 Sep |
|
Enhancement of hepatocarcinogenesis in female rats by ethinyl estradiol and mestranol but not estradiol. | 1984 Sep |
|
Xenobiotic interaction with and alteration of channel catfish estrogen receptor. | 1997 Dec |
|
Rapid yeast estrogen bioassays stably expressing human estrogen receptors alpha and beta, and green fluorescent protein: a comparison of different compounds with both receptor types. | 2004 Jul |
|
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006 Nov |
|
Rat α-Fetoprotein binding affinities of a large set of structurally diverse chemicals elucidated the relationships between structures and binding affinities. | 2012 Nov 19 |
Patents
Sample Use Guides
Dose starts on first day of menstrual cycle taking 1 tablet daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/536998
In vitro estrogen receptor binding affinity was determined using uterine cytosol preparation. Reaction mixture contained 0.7 ug of protein from the receptor preparation and 16000 dpm of 17beta[3H]estradiol in 0.25 mL of 0.01 Tris-HCl buffer, pH 8.0, containing 0.001 M EDTA and 0.25 M sucrose. Compound was tested in a dose-response fashion using 8 concentration from 0.1 nM to 100 000 nM in duplicate. After incubation at 4°C for 16-18 h, the compounds bound to the receptor were separated from those free in solution using dextran-coated charcoal. The amount of radioactivity bound to the receptor was quantified in Aquasol using liquid scintillation spectrometer. Mestranol did not bound to estrogen receptor in concetrations up to 100 uM, but its metabolite displaced estradiol with IC50 of 15 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000000100
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
||
|
NCI_THESAURUS |
C478
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
||
|
NDF-RT |
N0000175825
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
||
|
EPA PESTICIDE CODE |
115401
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
||
|
LIVERTOX |
607
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
72-33-3
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | |||
|
MESTRANOL
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | |||
|
1394008
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | USP-RS | ||
|
3588
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | |||
|
B2V233XGE7
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | |||
|
7087
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | |||
|
72-33-3
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | |||
|
6782
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | RxNorm | ||
|
1714
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | |||
|
SUB08791MIG
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | |||
|
1139
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | |||
|
C636
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | |||
|
6291
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | |||
|
DB01357
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | |||
|
D008656
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | |||
|
M7257
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | Merck Index | ||
|
CHEMBL1201151
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY | |||
|
200-777-8
Created by
admin on Fri Jun 25 20:54:41 UTC 2021 , Edited by admin on Fri Jun 25 20:54:41 UTC 2021
|
PRIMARY |
METABOLITE ACTIVE (PRODRUG)
SUBSTANCE RECORD